Top

Published in:

01-01-2016 | Special Feature

Molecular epidemiology, and possible real-world applications in breast cancer

Authors: Hidemi Ito, Keitaro Matsuo

Published in: Breast Cancer | Issue 1/2016

Abstract

Gene-environment interaction, a key idea in molecular epidemiology, has enabled the development of personalized medicine. This concept includes personalized prevention. While genome-wide association studies have identified a number of genetic susceptibility loci in breast cancer risk, however, the application of this knowledge to practical prevention is still underway. Here, we briefly review the history of molecular epidemiology and its progress in breast cancer epidemiology. We then introduce our experience with the trial combination of GWAS-identified loci and well-established lifestyle and reproductive risk factors in the risk prediction of breast cancer. Finally, we report our exploration of the cumulative risk of breast cancer based on this risk prediction model as a potential tool for individual risk communication, including genetic risk factors and gene-environment interaction with obesity.

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMedCrossRef

Harris CC, Weston A, Willey JC, Trivers GE, Mann DL. Biochemical and molecular epidemiology of human cancer: indicators of carcinogen exposure, DNA damage, and genetic predisposition. Environ Health Perspect. 1987;75:109–19.PubMedPubMedCentralCrossRef

Perera FP, Poirier MC, Yuspa SH, Nakayama J, Jaretzki A, Curnen MM, et al. A pilot project in molecular cancer epidemiology: determination of benzo[a]pyrene–DNA adducts in animal and human tissues by immunoassays. Carcinogenesis. 1982;3:1405–10.PubMedCrossRef

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.PubMedCrossRef

International HapMap C. The International HapMap Project. Nature. 2003;426:789–96.CrossRef

Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.CrossRef

IARC. Alcoholic beverage consumption and ethyl carbamate (urethane). IARC monographs on the evaluation of carcinogenic risks to humans 96. Lyon: International Agency for Research on Cancer; 2010.

WCRF/AICR. Alcoholic drinks. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007.

Yoshida A, Huang IY, Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci USA. 1984;81:258–61.PubMedPubMedCentralCrossRef

10.

Bosron WF, Crabb DW, Li TK. Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. Pharmacol Biochem Behav. 1983;18(Suppl 1):223–7.PubMedCrossRef

11.

Crabb DW, Edenberg HJ, Bosron WF, Li TK. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest. 1989;83:314–6.PubMedPubMedCentralCrossRef

12.

Li Y, Zhang D, Jin W, Shao C, Yan P, Xu C, et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest. 2006;116:506–11.PubMedPubMedCentralCrossRef

13.

Matsuo K, Wakai K, Hirose K, Ito H, Saito T, Tajima K. Alcohol dehydrogenase 2 His47Arg polymorphism influences drinking habit independently of aldehyde dehydrogenase 2 Glu487Lys polymorphism: analysis of 2,299 Japanese subjects. Cancer Epidemiol Biomarkers Prev. 2006;15:1009–13.PubMedCrossRef

14.

Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis. 2001;22:913–6.PubMedCrossRef

15.

Yang C, Wang H, Wang Z, Du H, Tao D, Mu X, et al. Risk factors for esophageal cancer: a case-control study in South-western China. Asian Pac J Cancer Prev. 2005;6:48–53.PubMed

16.

Hiraki A, Matsuo K, Wakai K, Suzuki T, Hasegawa Y, Tajima K. Gene-gene and gene-environment interactions between alcohol drinking habit and polymorphisms in alcohol-metabolizing enzyme genes and the risk of head and neck cancer in Japan. Cancer Sci. 2007;98:1087–91.PubMedCrossRef

17.

Oze I, Matsuo K, Hosono S, Ito H, Kawase T, Watanabe M, et al. Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. Cancer Sci. 2010;101:1875–80.PubMedCrossRef

18.

Matsuo K, Oze I, Hosono S, Ito H, Watanabe M, Ishioka K, et al. The aldehyde dehydrogenase 2 (ALDH2) Glu504Lys polymorphism interacts with alcohol drinking in the risk of stomach cancer. Carcinogenesis. 2013;34:1510–5.PubMedCrossRef

19.

Spitz MR, Bondy ML. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis. 2010;31:127–34.PubMedPubMedCentralCrossRef

20.

Thompson PA, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr. 2000;27:125–34.PubMedCrossRef

21.

Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef

22.

Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870–4.PubMedPubMedCentralCrossRef

23.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087–93.PubMedPubMedCentralCrossRef

24.

Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet. 2013;45:345–8.PubMedCrossRef

25.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRef

26.

Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.PubMedCrossRef

27.

Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99:1782–92.PubMedCrossRef

28.

Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103:951–61.PubMedPubMedCentralCrossRef

29.

Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110:535–45.PubMedPubMedCentralCrossRef

30.

Sueta A, Ito H, Kawase T, Hirose K, Hosono S, Yatabe Y, et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat. 2012;132:711–21.PubMedCrossRef

31.

Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362:986–93.PubMedPubMedCentralCrossRef

32.

Zheng W, Wen W, Gao YT, Shyr Y, Zheng Y, Long J, et al. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst. 2010;102:972–81.PubMedPubMedCentralCrossRef

33.

Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A Model of practical cancer prevention for out-patients visiting a hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev. 2000;1:35–47.PubMed

34.

Hamajima N, Matsuo K, Saito T, Hirose K, Inoue M, Takezaki T, et al. Gene-environment interactions and polymorphism studies of cancer risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACC-II). Asian Pac J Cancer Prev. 2001;2:99–107.PubMed

35.

Kawase T, Matsuo K, Suzuki T, Hiraki A, Watanabe M, Iwata H, et al. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. Int J Cancer. 2009;125:1946–52.PubMedCrossRef

36.

Travis RC, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet. 2010;375:2143–51.PubMedPubMedCentralCrossRef

37.

Brennan P, Crispo A, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, et al. High cumulative risk of lung cancer death among smokers and nonsmokers in Central and Eastern Europe. Am J Epidemiol. 2006;164:1233–41.PubMedCrossRef

38.

Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323–9.PubMedPubMedCentralCrossRef

39.

Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161:270–80.PubMedCrossRef

Title: Molecular epidemiology, and possible real-world applications in breast cancer
Authors: Hidemi Ito
Keitaro Matsuo
Publication date: 01-01-2016
Publisher: Springer Japan
Published in: Breast Cancer / Issue 1/2016
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-015-0609-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Genomic tumor evolution of breast cancer

Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization

Prediction of prone-to-supine tumor displacement in the breast using patient position change: investigation with prone MRI and supine CT

Multi-gene classifiers for prediction of recurrence in breast cancer patients

A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy

Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer